Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has earned an average recommendation of “Hold” from the seven ratings firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $4.16.
Several research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $3.00 target price on shares of Sunesis Pharmaceuticals in a research report on Wednesday, September 27th. UBS Group assumed coverage on Sunesis Pharmaceuticals in a research report on Monday, November 20th. They issued an “outperform” rating on the stock. Oppenheimer assumed coverage on Sunesis Pharmaceuticals in a research report on Tuesday, November 21st. They issued an “outperform” rating and a $7.00 target price on the stock. Wells Fargo & Co raised Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their target price for the stock from $2.86 to $2.48 in a research report on Monday, December 11th. Finally, Cowen reaffirmed a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Thursday, November 2nd.
Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) traded up $0.24 during mid-day trading on Wednesday, reaching $4.25. The company’s stock had a trading volume of 138,920 shares, compared to its average volume of 227,304. The company has a debt-to-equity ratio of -0.34, a quick ratio of 1.84 and a current ratio of 1.84. Sunesis Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $4.45. The firm has a market cap of $145.56, a price-to-earnings ratio of -2.43 and a beta of 1.53.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.06). During the same period in the prior year, the business earned ($0.62) earnings per share. sell-side analysts forecast that Sunesis Pharmaceuticals will post -1.58 earnings per share for the current fiscal year.
In related news, major shareholder Mpm Oncology Impact Management acquired 25,300 shares of the stock in a transaction dated Thursday, November 2nd. The shares were acquired at an average price of $2.59 per share, with a total value of $65,527.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Dayton Misfeldt acquired 400,000 shares of the stock in a transaction dated Friday, October 27th. The shares were bought at an average cost of $2.00 per share, for a total transaction of $800,000.00. The disclosure for this purchase can be found here. In the last three months, insiders have bought 506,800 shares of company stock worth $1,091,282. 10.21% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently modified their holdings of SNSS. Wells Fargo & Company MN increased its holdings in shares of Sunesis Pharmaceuticals by 77.4% during the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 18,254 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Sunesis Pharmaceuticals by 4.1% during the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after acquiring an additional 23,819 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals during the 2nd quarter valued at about $208,000. Finally, Balyasny Asset Management LLC acquired a new position in shares of Sunesis Pharmaceuticals during the 2nd quarter valued at about $5,400,000. 38.21% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/13/analysts-set-sunesis-pharmaceuticals-inc-snss-price-target-at-4-16.html.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.